



**Date:** July 06, 2022  
**Subject:** GSK plc – Anticipated Distribution/Share Consolidation  
Option Symbol: GSK  
New Symbol: GSK1  
Date: 07/19/2022???

GSK plc (GSK) has announced a distribution of (New) Haleon plc (HLN) American Depositary Shares. The distribution ratio is 1.0 of an HLN share for each existing GSK share held. The record date is July 15, 2022; the payable date is July 21, 2022. The ex-distribution date is anticipated to be July 19, 2022.

Immediately following the distribution, GSK ADSs will undergo a share consolidation at a ratio (“GSK Share Consolidation Ratio”) that is to be determined. Cash will be paid in lieu of fractional GSK ADSs in connection with the GSK Share Consolidation.

Haleon plc American Depositary Shares are expected to begin trading on a when issued basis on July 18, 2022 on the NYSE under the trading symbol “HLN W1”. (New) Post-Split GSK American Depositary Shares are expected to begin trading on a when issued basis on July 19, 2022 on the NYSE under the trading symbol “GSK W1”. HLN and GSK both are expected to begin regular way trading on July 22, 2022.

**Contract Adjustment**

**Effective Date:** July 19, 2022???  
**Option Symbol:** GSK changes to GSK1  
**Strike Prices:** No Change  
**Number of Contracts:** No Change  
**Multiplier:** 100 (e.g., a premium of 1.50 yields \$150; a strike of 45 yields \$4,500.00)

**New Deliverable Per Contract:**  
1) A number, equal to the GSK Share Consolidation Ratio x 100, of (New) GSK plc (GSK) American Depositary Shares (subject to delayed settlement until the ratio is determined and until regular way trading commences)  
2) 100 (New) Haleon plc (HLN) American Depositary Shares (subject to delayed settlement until regular way trading commences)  
3) Cash in lieu of fractional (New) GSK ADSs, if any

Note: Once determined, the cash in lieu of fractional share portion of the option deliverable will remain fixed and will not vary with price changes of any security.

**Settlement**

**Allocation:** GSK: TBD  
HLN: TBD

**CUSIPs:** (New) GSK: 37733W204  
(New) HLN: 405552100

THE SETTLEMENT ALLOCATION OF THE TOTAL STRIKE PRICE AMOUNT IS BEING PROVIDED SOLELY FOR THE PURPOSE OF THE INTERFACE BETWEEN OCC AND THE NATIONAL SECURITY CLEARING CORPORATION (NSCC), AND IS NOT INTENDED TO BE USED FOR ANY OTHER PURPOSE, TRANSACTION OR CUSTOMER ACCOUNT STATEMENTS.

**Delayed Settlement**

OCC will delay settlement of the GSK and HLN components and the cash portion, if any, of the GSK1 deliverable until the share consolidation ratio is determined, until the cash in lieu amount, if any, is determined, and until regular way trading in GSK and HLN shares commences. Upon determination of the final share consolidation ratio and cash in lieu amount, and upon commencement of regular way trading, OCC will require Put exercisers and Call assignees to deliver the appropriate number of GSK and HLN shares and the appropriate cash amount, if any.

**Disclaimer**

This Information Memo provides an unofficial summary of the terms of corporate events affecting listed options or futures prepared for the convenience of market participants. OCC accepts no responsibility for the accuracy or completeness of the summary, particularly for information which may be relevant to investment decisions. Option or futures investors should independently ascertain and evaluate all information concerning this corporate event(s).

The determination to adjust options and the nature of any adjustment is made by OCC pursuant to OCC By-Laws, Article VI, Sections 11 and 11A. The determination to adjust futures and the nature of any adjustment is made by OCC pursuant to OCC By-Laws, Article XII, Sections 3, 4, or 4A, as applicable. For both options and futures, each adjustment decision is made on a case by case basis. Adjustment decisions are based on information available at the time and are subject to change as additional information becomes available or if there are material changes to the terms of the corporate event(s) occasioning the adjustment.

**ALL CLEARING MEMBERS ARE REQUESTED TO IMMEDIATELY ADVISE ALL BRANCH OFFICES AND CORRESPONDENTS ON THE ABOVE.**

For questions regarding this memo, please email the Investor Education team at [options@theocc.com](mailto:options@theocc.com). Clearing Member Firms of OCC may contact Member Services at 1-800-544-6091 or, within Canada, at 1-800-424-7320, or email [memberservices@theocc.com](mailto:memberservices@theocc.com).